From: Overview of systematic reviews of therapeutic ranges: methodologies and recommendations for practice
Study | Intervention | Comparator | Outcome |
---|---|---|---|
Pryblyski 2015 [13] | Vancomycin serum levels >15Â mg/l | Vancomycin serum levels <15Â mg/l | Mortality, persistent bacteraemia |
Moreau 2014 [17] | Patients with serum TGN concentrations above 230Â pmol/ pmol/8.10^8 | Patients with serum TGN concentrations below pmol/8.10^8 | Clinical remission of inflammatory bowel disease |
Osterman 2006 [12] | Patients with serum TGN concentrations above predetermined threshold | Patients with serum TGN concentrations below predetermined threshold | Clinical remission of inflammatory bowel disease |
Osterman 2006 [12] | Patients with active disease | Patients in clinical remission | Serum TGN levels |
Bishara 2013 [16] | High serum olanzapine concentrations | Low serum olanzapine concentrations | PANSS |